Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
9 Meters Biopharma is a business based in the US. 9 Meters Biopharma stocks (INNT.US) are listed on the NASDAQ and all prices are listed in US Dollars. 9 Meters Biopharma employs 8 staff and has a market cap (total outstanding stock value) of $23.1 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$N/A|
|52-week range||$0.6622 - $0.87|
|50-day moving average||$0.7269|
|200-day moving average||$0.6081|
|Wall St. target price||$10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.491|
Note: The dollar amounts in the table below are in Canadian dollars.
|Gross profit TTM||USD$0|
|Return on assets TTM||-193.21%|
|Return on equity TTM||0%|
|Market capitalisation||USD$23.1 million|
TTM: trailing 12 months
There are currently 2.2 million 9 Meters Biopharma stocks held short by investors – that's known as 9 Meters Biopharma's "short interest". This figure is 1.7% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting 9 Meters Biopharma stocks can be evaluated.
9 Meters Biopharma's "short interest ratio" (SIR) is the quantity of 9 Meters Biopharma stocks currently shorted divided by the average quantity of 9 Meters Biopharma stocks traded daily (recently around 519741.86602871). 9 Meters Biopharma's SIR currently stands at 4.18. In other words for every 100,000 9 Meters Biopharma stocks traded daily on the market, roughly 4180 stocks are currently held short.
However 9 Meters Biopharma's short interest can also be evaluated against the total number of 9 Meters Biopharma stocks, or, against the total number of tradable 9 Meters Biopharma stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 9 Meters Biopharma's short interest could be expressed as 0.03% of the outstanding stocks (for every 100,000 9 Meters Biopharma stocks in existence, roughly 30 stocks are currently held short) or 0.027% of the tradable stocks (for every 100,000 tradable 9 Meters Biopharma stocks, roughly 27 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against 9 Meters Biopharma.
Find out more about how you can short 9 Meters Biopharma stock.
We're not expecting 9 Meters Biopharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
9 Meters Biopharma stocks were split on a 1:10 basis on 1 February 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 9 Meters Biopharma stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for 9 Meters Biopharma stocks which in turn could have impacted 9 Meters Biopharma's stock price.
Over the last 12 months, 9 Meters Biopharma's stocks have ranged in value from as little as $0.6622 up to $0.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while 9 Meters Biopharma's is -0.5435. This would suggest that 9 Meters Biopharma's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, 9 Meters Biopharma has bucked the trend.
9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.
Everything we know about the Vaccinex IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.